Translational Oncology for Drug Development

Orthotopic PDX xenograft models are a superior offering for simulating oncology clinical trials.


Key links for pharmaceutical companies:

Tumor Banking 

Clinical Results


Certis Oncology is established as a leader in translational research.  Our studies have demonstrated that disease progression and subsequent metastasis in mice mimics the clinical progression in humans.

Orthotopic PDX models are proven to be more clinically relevant than PDX.  

We provide the world’s only orthotopic models utilizing Surgical Orthotopic Implantation. Only Orthotopic PDX models metastasize similar to clinical cancer. In Orthotopic PDX models, the primary tumor develops in the organ corresponding to its origin and metastasizes to mimic the complexity of tumor behavior in patients. Orthotopic PDX models are therefore the most clinically relevant for drug discovery and evaluation.

Orthotopic PDX’s multiple simultaneous implants increases the accuracy of therapy and reduces the time to treat aggressive tumors.  This provides a significant, sustainable competitive advantage over existing mouse models.

Orthotopic PDX provides expanded opportunities over traditional PDX and CDX models.

  • Allows the evaluation of anti-metastatic effects of agents, given the propensity of orthotopically implanted tumors to metastasize.
  • Less susceptible to false positives and false negatives than subcutaneous implanted tumors.
  • Delivers the ability to survey a wide variety of tumor types to confirm Responder ID hypotheses.
  • Shown to maintain genetic fidelity from patient material through several passages.

With our Orthotopic PDXs, you can perform next-generation studies, including:

  • Drug screening for efficacy against Orthotopic PDXs of multiple cancer types
  • Drug sensitivity

Typical Orthotopic PDX study endpoints

  • Tumor size reduction and regression
  • Tumor growth delay or regression
  • Decrease or elimination of metastasis
  • Drug effects on host as well as tumors
  • Increase in overall survival and disease-free survival
  • Changes in biomarkers
  • Tumor histology
  • Tumor immunohistochemistry.